Pfizer GDF15 Monoclonal Antibody Ponsegromab Injection Applied for Clinical Application
On May 10, CDE's official website showed that Pfizer's clinical trial application for Ponsegromab injection was accepted. This is the first GDF15 monoclonal antibody to be declared for clinical application in China, which can be used for the treatment of cancer cachexia, solid tumors, anorexia, heart failure, etc.
Ponsegromab is currently mainly developed for the treatment of cancer cachexia (cancer cachexia). This is a secondary reaction characterized by systemic metabolic disorders mainly caused by tumor cell products and cytokines released by the body, manifested as loss of appetite, weight loss, anemia, weakness, and exhaustion. About 20% of cancer patients' deaths are related to cancer cachexia.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
How Can Investors Benefit from Pfizer's Dividend Yield for a Monthly Income?
-
Pfizer's Revenue Forecast Disappoints, Stock Plummets: A Closer Look at the Challenges Ahead
-
Pfizer's Angela Hwang Departs as Company Completes Seagen Acquisition and Establishes New Oncology Division
-
2023 Senior Management Personnel Changes of Multinational Pharmaceutical Companies in China, what's behind it? - III
-
Milestone Approvals in Sickle Cell Disease (SCD): FDA Approves Two Therapies before Pfizer's GBT601 Disclosure
-
Pfizer's Strategic Shift in China's Pneumococcal Vaccine Market
-
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)
-
Pfizer: In 2023, COVID-19's product revenue will decline significantly
-
25 million with one injection?! The record for 'the world's most expensive drug' is still controversial...
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
Recommend Reading
-
![BASF Partners with Sinopec to Accelerate Application of Biomethane at Nanjing]()
BASF Partners with Sinopec to Accelerate Application of Biomethane at Nanjing
-
![From LANXESS’s 50% to Tire Makers’ 5%: The Rubber Industry Chain Is Experiencing a “Decreasing-Cost Transmission”]()
From LANXESS’s 50% to Tire Makers’ 5%: The Rubber Industry Chain Is Experiencing a “Decreasing-Cost Transmission”
-
![Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China]()
Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China
-
![Givaudan Introduces New Labdanum Absolute for Fragrance Creations]()
Givaudan Introduces New Labdanum Absolute for Fragrance Creations
-
![Lilly Bets US$3 Billion on China While Simultaneously Cracking Down on the Gray Market for Weight-Loss Drugs]()
Lilly Bets US$3 Billion on China While Simultaneously Cracking Down on the Gray Market for Weight-Loss Drugs
-
![Business Society’s Crude Oil Market Outlook on August 20, 2026: Upside Momentum Fades]()
Business Society’s Crude Oil Market Outlook on August 20, 2026: Upside Momentum Fades
-
![Business Society’s Market Outlook for Petroleum Coke on August 19, 2026: Decline]()
Business Society’s Market Outlook for Petroleum Coke on August 19, 2026: Decline
-
![Business Society’s Ethanol Market Outlook on August 19, 2026: Slightly Bullish with Volatile Fluctuations]()
Business Society’s Ethanol Market Outlook on August 19, 2026: Slightly Bullish with Volatile Fluctuations
-
![Cost Decline, Weak Demand—Oxynol Prices Fluctuate and Fall This Week]()
Cost Decline, Weak Demand—Oxynol Prices Fluctuate and Fall This Week
-
![Business Society’s August 19, 2026 Ethyl Acetate Market Outlook: Strong Consolidation]()
Business Society’s August 19, 2026 Ethyl Acetate Market Outlook: Strong Consolidation
